Eli Lilly Reports Stellar Q1 Performance

Eli Lilly announced a remarkable 45% increase in revenue for the first quarter of fiscal 2025, reaching $12.73 billion. This growth was primarily driven by the soaring demand for its weight-loss and diabetes medications, Mounjaro and Zepbound.

Financial Highlights and Future Plans

The company's net income saw a 23% year-over-year increase, totaling $2.76 billion. Despite facing $1.57 billion in acquired in-process R&D charges, earnings per share stood strong at $3.06. CEO David Ricks shared exciting updates on the company's oral GLP-1 candidate, forgilzumab, and reaffirmed the annual revenue guidance between $58 billion and $61 billion.

In response to the escalating demand, Eli Lilly also unveiled ambitious plans for a $50 billion expansion of its US manufacturing capabilities.